Analyst Consensus ?
ConsensusHold34 ratings
Bullish1750.0%
Neutral1441.2%
Bearish38.8%
Henry Schein, Inc. · HSIC · FY2024 Q4 · Calendar Q1 2025
Henry Schein highlights margin gains amid modest 2025 outlook
The supplied analysis supports a balanced view: Henry Schein is showing operational improvement and broader contribution from higher-growth businesses, but the near-term revenue outlook is modest and execution, pricing and market risks remain material.
Reported Before market openNASDAQHealthcare
$9.69B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.23
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $3.29B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-2.3%
Event window
SPY move
-0.5%
Same window
Abnormal move
-1.8%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
-8.5%
Up to 20 sessions
HSICSPY benchmark
Ask FN2 about HSIC FY2024 Q4
Transcript, numbers and history already loaded
What drove HSIC's -2.3% move after FY2024 Q4 earnings?What changed in HSIC's guidance and outlook in FY2024 Q4?Give me the bull and bear case for HSIC after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the analysis points to completion of the BOLD+1 plan, high-growth and high-margin businesses contributing over half of operating income, the Acentus acquisition, a strategic KKR partnership, new segment reporting and 2025 guidance for 2%-4% sales growth.
Guidance delta
Maintained; management provided 2025 guidance of 2%-4% sales growth and modest EPS upside.
Key takeaways
- Management described a strong fourth quarter with double-digit margin improvement and cash flow generation.
- High-growth, high-margin businesses now contribute over half of operating income, according to the supplied analysis.
- The 2025 outlook calls for 2%-4% sales growth, with high-single-digit to low-double-digit EPS growth expected thereafter.
- Dental implants, practice-management SaaS, U.S. e-commerce expansion and Acentus were identified as growth drivers.
- The BOLD+1 plan was completed, while new segment reporting and leadership changes aim to improve focus and transparency.
Management priorities
- Execute the 2025-2027 BOLD+1 strategic plan with KKR partnership support.
- Roll out the U.S. e-commerce platform and AI-enabled clinical workflow solutions.
- Expand dental implants, cloud practice-management SaaS and recurring revenue.
- Integrate Acentus and advance the Home Solutions portfolio.
- Deliver restructuring savings and improve operating efficiency.
Follow HSIC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$85.03Current
$64Low
$87.38Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 14, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Aug 19, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 6, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 5, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Jul 29, 2026 |
| Mizuho | Neutral | Neutral | Maintain | May 6, 2026 |
| Morgan Stanley | Underweight | Underweight | Maintain | Apr 24, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 25, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Feb 25, 2026 |
| Barrington Research | Outperform | Outperform | Maintain | Feb 25, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Feb 24, 2026 |
| Baird | Outperform | Neutral | Upgrade | Feb 23, 2026 |
| Stifel | Hold | Buy | Downgrade | Jul 25, 2025 |
| Jefferies | Hold | Hold | Maintain | Jan 23, 2025 |
| B of A Securities | Buy | Underperform | Upgrade | Jan 6, 2025 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 8, 2023 |
| Goldman Sachs | Neutral | Buy | Downgrade | Jul 21, 2022 |
| CFRA | Hold | Hold | Maintain | May 5, 2020 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Apr 2, 2020 |
| Bank of America | Neutral | Neutral | Maintain | Dec 3, 2019 |
| William Blair | Market Perform | Outperform | Downgrade | Aug 7, 2019 |
| SVB Leerink | Market Perform | Outperform | Downgrade | May 15, 2019 |
| Guggenheim | Buy | Buy | Maintain | Apr 18, 2019 |
| Edward Jones | Sell | Hold | Downgrade | Oct 25, 2018 |
| Stifel Nicolaus | Hold | Hold | Maintain | Aug 7, 2018 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 24, 2018 |
| Leerink Swann | Outperform | Market Perform | Upgrade | Apr 4, 2018 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Nov 28, 2017 |
| Craig-Hallum | Buy | Hold | Upgrade | Nov 7, 2017 |
| RBC Capital | Perform | Sector Perform | Maintain | Sep 19, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Sep 15, 2017 |
| Gabelli & Co. | Buy | Hold | Upgrade | Jan 10, 2017 |
| ISI Group | Underweight | Underweight | Maintain | Jul 12, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $85.03. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BTIG | David Larsen | $110 | $90.62 | +29.4% | Aug 19, 2026 |
| Barclays | Analyst unavailable | $100 | $89.59 | +17.6% | Aug 6, 2026 |
| Barrington | Michael Petusky | $104 | $89.11 | +22.3% | Aug 5, 2026 |
| UBS | Kevin Caliendo | $94 | $89.11 | +10.5% | Aug 5, 2026 |
| Stifel Nicolaus | Analyst unavailable | $95 | $89.11 | +11.7% | Aug 5, 2026 |
| UBS | Analyst unavailable | $89 | $85.88 | +4.7% | Jul 28, 2026 |
| BMO Capital | Vik Chopra | $85 | $83.22 | -0.0% | Jul 8, 2026 |
| BTIG | Analyst unavailable | $100 | $78.85 | +17.6% | Jun 11, 2026 |
| UBS | Kevin Caliendo | $85 | $74.35 | -0.0% | May 6, 2026 |
| Mizuho Securities | Analyst unavailable | $82 | $74.37 | -3.6% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $97 | $74.37 | +14.1% | May 6, 2026 |
| Morgan Stanley | Erin Wright | $64 | $78.22 | -24.7% | Apr 24, 2026 |
| Barrington | Analyst unavailable | $97 | $81.6 | +14.1% | Feb 25, 2026 |
| Leerink Partners | Analyst unavailable | $87 | $83.35 | +2.3% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $100 | $79.57 | +17.6% | Feb 23, 2026 |
| Mizuho Securities | Steven Valiquette | $81 | $79.98 | -4.7% | Jan 20, 2026 |
| Barclays | Analyst unavailable | $86 | $72.86 | +1.1% | Dec 8, 2025 |
| Evercore ISI | Analyst unavailable | $90 | $71.68 | +5.8% | Nov 5, 2025 |
| Barrington | Analyst unavailable | $79 | $71.32 | -7.1% | Nov 5, 2025 |
| Evercore ISI | Analyst unavailable | $83 | $69.04 | -2.4% | Aug 26, 2025 |
| Leerink Partners | Michael Cherny | $75 | $70.8 | -11.8% | Jul 14, 2025 |
| Barrington | Michael Petusky | $86 | $66.24 | +1.1% | May 6, 2025 |
| CFRA | Daniel Rich | $67 | $71.1 | -21.2% | Oct 15, 2024 |
| Evercore ISI | Elizabeth Anderson | $74 | $69.3 | -13.0% | Oct 8, 2024 |
| Robert W. Baird | Jeff Johnson | $92 | $70.34 | +8.2% | Jul 22, 2024 |
| Stifel Nicolaus | Jonathan Block | $70 | $64.07 | -17.7% | Nov 13, 2023 |
| Stifel Nicolaus | Jonathan Block | $80 | $73.17 | -5.9% | Jun 17, 2022 |
| Robert W. Baird | Jeff Johnson | $88 | $78.82 | +3.5% | Jun 14, 2022 |
| Barclays | Steven Valiquette | $82 | $77.3 | -3.6% | Aug 4, 2021 |
Track every rating change on HSIC the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationHenry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment.…
Historical context
All HSIC earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| JNJ Johnson & Johnson | FY2026 Q3 · Calendar Q4 2026 | +2.8% | -5.7% | J&J raises outlook as oncology leads, while MedTech lags |
| UNH UnitedHealth Group Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.5% | UnitedHealth raises 2026 EPS outlook as AI and care initiatives advance |
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
Latest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the HSIC recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-02-11T00:01:39.744939+00:00
- Polygon adjusted daily market bars · 2026-10-14T02:30:42.032372+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-14T02:30:42.029326+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-14. For educational purposes only; not investment advice.